Observational studyFrontiers in endocrinology2026
Changes in retinal venous diameter in proliferative diabetic retinopathy patients with diabetic macular edema following faricimab treatment: an observational study.
Observational study in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: To evaluate the effect of intravitreal faricimab injections on retinal venous diameter in proliferative diabetic retinopathy (PDR) patients with diabetic macular edema (DME). Methods: This single-center, retrospective cohort study included 46 PDR patients (46 eyes) with DME, treated between August 2024 and January 2025. All participants received intravitreal faricimab combined with panretinal photocoagulation (PRP). Best-corrected visual acuity (BCVA, logMAR), central foveal thickness (CFT, μm), microaneurysm (MA) count, hard exudates (HE), neovascularization (NV) area, and retinal venous diameter were assessed at baseline and at 1, 3, and 6 months post-treatment. Results: Significant improvements in BCVA were observed at 1, 3, and 6 months (0.52 ± 0.16, 0.48 ± 0.18, 0.40 ± 0.15 vs. baseline 0.66 ± 0.18; all P < 0.05). CFT showed a significant reduction at all time points (381.35 ± 40.75, 327.30 ± 43.40, 297.56 ± 35.81 μm vs. baseline 472.34 ± 47.23 μm; all P < 0.05). The MA count showed no significant reduction at 1 month (P > 0.05) but decreased significantly thereafter (72.71 ± 20.53 and 63.06 ± 17.08 at 3 and 6 months, respectively; both P < 0.05). Reductions in HE area were not significant at 1 or 3 months (in 2 and 6 patients, respectively; both P > 0.05). At 6 months, a significant reduction in HE area was observed in 14 patients (P < 0.05). The NV area was significantly reduced at 1, 3, and 6 months compared to baseline (0.17 ± 0.10 mm², 0.17 ± 0.09 mm², and 0.17 ± 0.08 mm² vs. 0.98 ± 0.17 mm²; all P<0.05). Retinal venous diameter showed no significant change at 1 and 3 months compared with baseline (both P > 0.05) but was significantly reduced at 6 months (299.40 ± 19.56 μm; P < 0.05). Conclusion: Intravitreal faricimab was safe and effective for PDR patients with DME. A trend toward morphological reversal of retinal venous diameter was demonstrated at 6 months, suggesting that faricimab may influence retinal microvascular remodeling through dual inhibition of the VEGF-A and Ang-2 pathways.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.